Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zachary Kincaid

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Journal of Visualized Experiments : Jove|January 22, 2019
Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene DependenceMeenu Kesarwani, Zachary Kincaid, Mohammad Azam
Journal of Visualized Experiments : Jove|December 31, 2014
A method for screening and validation of resistant mutations against kinase inhibitorsMeenu Kesarwani, Erika Huber, Zachary Kincaid, et al.
Blood Advances|March 26, 2024
Enhanced MAPK signaling induced by CSF3R mutants confers dependence to DUSP1 for leukemic transformationMeenu Kesarwani, Zachary Kincaid, Mohammad Azhar, et al.
European Journal of Sport Science|September 10, 2019
A preliminary investigation of acute exercise intensity on memory and BDNF isoform concentrationsAaron T Piepmeier, Jennifer L Etnier, Laurie Wideman, et al.
Blood Advances|November 12, 2021
Momelotinib is a highly potent inhibitor of FLT3-mutant AMLMohammad Azhar, Zachary Kincaid, Meenu Kesarwani, et al.
Leukemia|July 10, 2023
MAPK-negative feedback regulation confers dependence to JAK2<sup>V617F</sup> signalingMeenu Kesarwani, Zachary Kincaid, Mohammad Azhar, et al.
Scientific Reports|October 1, 2015
Targeting substrate-site in Jak2 kinase prevents emergence of genetic resistanceMeenu Kesarwani, Erika Huber, Zachary Kincaid, et al.
Blood Advances|August 31, 2022
Rational polypharmacological targeting of FLT3, JAK2, ABL, and ERK1 suppresses the adaptive resistance to FLT3 inhibitors in AMLMohammad Azhar, Zachary Kincaid, Meenu Kesarwani, et al.
Nature Medicine|March 21, 2017
Targeting c-FOS and DUSP1 abrogates intrinsic resistance to tyrosine-kinase inhibitor therapy in BCR-ABL-induced leukemiaMeenu Kesarwani, Zachary Kincaid, Ahmed Gomaa, et al.
Medrxiv : the Preprint Server for Health Sciences|May 4, 2026
A novel hyperactive <i>BCR::ABL1</i> <sup><i>e6a3</i></sup> variant confers resistance to combined asciminib plus ponatinib therapyValentina Nardi, Joshua Schwieterman, Sekhu Ansari, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Journal of Visualized Experiments : Jove|January 22, 2019
Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene DependenceMeenu Kesarwani, Zachary Kincaid, Mohammad Azam
Journal of Visualized Experiments : Jove|December 31, 2014
A method for screening and validation of resistant mutations against kinase inhibitorsMeenu Kesarwani, Erika Huber, Zachary Kincaid, et al.
Blood Advances|March 26, 2024
Enhanced MAPK signaling induced by CSF3R mutants confers dependence to DUSP1 for leukemic transformationMeenu Kesarwani, Zachary Kincaid, Mohammad Azhar, et al.
European Journal of Sport Science|September 10, 2019
A preliminary investigation of acute exercise intensity on memory and BDNF isoform concentrationsAaron T Piepmeier, Jennifer L Etnier, Laurie Wideman, et al.
Blood Advances|November 12, 2021
Momelotinib is a highly potent inhibitor of FLT3-mutant AMLMohammad Azhar, Zachary Kincaid, Meenu Kesarwani, et al.
Leukemia|July 10, 2023
MAPK-negative feedback regulation confers dependence to JAK2<sup>V617F</sup> signalingMeenu Kesarwani, Zachary Kincaid, Mohammad Azhar, et al.
Scientific Reports|October 1, 2015
Targeting substrate-site in Jak2 kinase prevents emergence of genetic resistanceMeenu Kesarwani, Erika Huber, Zachary Kincaid, et al.
Blood Advances|August 31, 2022
Rational polypharmacological targeting of FLT3, JAK2, ABL, and ERK1 suppresses the adaptive resistance to FLT3 inhibitors in AMLMohammad Azhar, Zachary Kincaid, Meenu Kesarwani, et al.
Nature Medicine|March 21, 2017
Targeting c-FOS and DUSP1 abrogates intrinsic resistance to tyrosine-kinase inhibitor therapy in BCR-ABL-induced leukemiaMeenu Kesarwani, Zachary Kincaid, Ahmed Gomaa, et al.
Medrxiv : the Preprint Server for Health Sciences|May 4, 2026
A novel hyperactive <i>BCR::ABL1</i> <sup><i>e6a3</i></sup> variant confers resistance to combined asciminib plus ponatinib therapyValentina Nardi, Joshua Schwieterman, Sekhu Ansari, et al.
Pageof 1